ZOMETA® effectively helps to protect patients with breast cancer
from the threat of SREs
Efficacy of ZOMETA vs placebo in a Japanese study of patients
with breast cancer and bone metastases: median time to first SRE5
- ZOMETA significantly extended time to first SRE vs placebo (median not reached vs 364 days, respectively; P=.007)5
- ZOMETA reduced the relative risk of SREs vs placebo by 40%5
- ZOMETA demonstrated efficacy equivalent to pamidronate in delaying median time to first SRE in an additional noninferiority trial in patients with breast cancer or multiple myeloma7
ZOMETA can delay and reduce SREs in patients with breast cancer and
bone metastases5,7
